NO20060241L - Frysetorket FSH/LH-formuleringer - Google Patents

Frysetorket FSH/LH-formuleringer

Info

Publication number
NO20060241L
NO20060241L NO20060241A NO20060241A NO20060241L NO 20060241 L NO20060241 L NO 20060241L NO 20060241 A NO20060241 A NO 20060241A NO 20060241 A NO20060241 A NO 20060241A NO 20060241 L NO20060241 L NO 20060241L
Authority
NO
Norway
Prior art keywords
formulations
freeze
fsh
dried fsh
dried
Prior art date
Application number
NO20060241A
Other languages
English (en)
Other versions
NO330210B1 (no
Inventor
Fabrizio Samaritani
Piergiorgio Donati
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33522382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060241(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20060241L publication Critical patent/NO20060241L/no
Publication of NO330210B1 publication Critical patent/NO330210B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår området farmasøytiske formuleringer av en blanding follikkelstimulerende hormon (FSH) og luteiniserende hormon (LH) og fremgangsmåter for å fremstille slike formuleringer.
NO20060241A 2003-06-20 2006-01-17 Frysetorkede formuleringer av follikkelstimulerende hormon (FSH) og luteiniserende hormon (LH), fremgangsmate for fremstilling av samme og industriell artikkel omfattende de frysetorkete formuleringene. NO330210B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101830 2003-06-20
PCT/EP2004/051138 WO2004112826A1 (en) 2003-06-20 2004-06-16 Freeze-dried fsh / lh formulations

Publications (2)

Publication Number Publication Date
NO20060241L true NO20060241L (no) 2006-01-17
NO330210B1 NO330210B1 (no) 2011-03-07

Family

ID=33522382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060241A NO330210B1 (no) 2003-06-20 2006-01-17 Frysetorkede formuleringer av follikkelstimulerende hormon (FSH) og luteiniserende hormon (LH), fremgangsmate for fremstilling av samme og industriell artikkel omfattende de frysetorkete formuleringene.

Country Status (15)

Country Link
US (1) US7740884B2 (no)
EP (1) EP1638595B1 (no)
JP (1) JP4871124B2 (no)
AU (1) AU2004248931B2 (no)
CA (1) CA2526099C (no)
CY (1) CY1114121T1 (no)
DK (1) DK1638595T3 (no)
ES (1) ES2414705T3 (no)
HR (1) HRP20130242T1 (no)
IL (1) IL172353A (no)
NO (1) NO330210B1 (no)
PL (1) PL1638595T3 (no)
PT (1) PT1638595E (no)
SI (1) SI1638595T1 (no)
WO (1) WO2004112826A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
CN101347613B (zh) * 2008-09-17 2011-10-26 上海天伟生物制药有限公司 几乎不含亚基的糖蛋白的组合物及其制备方法
WO2011076117A1 (zh) * 2009-12-22 2011-06-30 上海天伟生物制药有限公司 绝经期促性腺素组合物
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
CN108096199B (zh) * 2018-01-15 2020-08-25 常州市第四制药厂有限公司 一种注射用奥美拉唑钠及制备方法
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
AR117743A1 (es) 2019-12-30 2021-08-25 Univ Nacional Del Litoral Unl MÉTODO DE OBTENCIÓN DE UNA LÍNEA CELULAR DE MAMÍFERO QUE EXPRESA UNA HORMONA GONADOTROFINA CORIÓNICA EQUINA RECOMBINANTE (reCG), LÍNEA CELULAR QUE EXPRESA reCG, MÉTODO DE PRODUCCIÓN A ESCALA DE reCG, reCG, FORMULACIONES QUE LA CONTIENEN, ÁCIDOS NUCLEICOS QUE CODIFICAN PARA reCG Y USOS

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
FR3819M (fr) 1963-03-11 1966-01-10 Serono Ist Farm Nouvelle hormone hypophysaire a activité différenciée.
DE3262575D1 (en) 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS5921613A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4780451B1 (en) 1987-01-23 1995-04-04 Asua International Inc Composition and method for producing superovulation in cattle
US5162306A (en) * 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE3863908D1 (de) 1987-11-27 1991-08-29 Akzo Nv Stabilisierung von antikoerpern.
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5087615A (en) 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
US5270057A (en) 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
DE4117078A1 (de) 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
US5508261A (en) 1991-06-18 1996-04-16 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
EP0673383B1 (en) 1991-06-18 2000-05-31 University Of Medicine & Dentistry Of New Jersey Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5356876A (en) 1992-01-13 1994-10-18 Trinity University Methods of terminating pregnancy
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
CA2489978A1 (en) 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
CN1163264C (zh) 1993-02-02 2004-08-25 爱克索马技术有限公司 改进的药物组合物
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
DE69508985T2 (de) 1994-02-21 1999-08-19 Takeda Chemical Industries Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
CA2208484C (en) 1994-12-22 2008-09-23 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
SI2275119T1 (sl) 1995-07-27 2013-12-31 Genentech, Inc. Stabilna izotonična liofilizirana proteinska formulacija
DK0862452T3 (da) 1995-11-07 2004-04-05 Genentech Inc Stabiliserende formulering af NGF
RU2183110C2 (ru) 1996-12-23 2002-06-10 Ново Нордиск А/С Медикаментозный контейнер из линейного олефинового полимера для хранения жидкого медикамента
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US7311912B1 (en) 1997-01-10 2007-12-25 Plantbodies Corporation Epithelial tissue targeting agent
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20010007673A1 (en) 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
DE69811233T2 (de) 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
IL140984A0 (en) 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
FR2782455B3 (fr) 1998-08-20 2000-09-15 Sanofi Sa Composition pharmaceutique injectable a base d'un sel pharmaceutiquement acceptable du clopidogrel ou de ticlopidine
CA2343268A1 (en) 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
ES2267531T5 (es) 1999-05-07 2015-11-24 Merck Serono Sa Uso de LH administrada en la fase folicular media o tardía para el tratamiento de mujeres anovulatorias
PL353065A1 (en) 1999-06-30 2003-10-06 Takeda Chemical Industries, Ltd. Novel polypeptide and dna thereof
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations

Also Published As

Publication number Publication date
JP4871124B2 (ja) 2012-02-08
CA2526099A1 (en) 2004-12-29
WO2004112826A1 (en) 2004-12-29
CY1114121T1 (el) 2016-07-27
EP1638595B1 (en) 2013-03-20
SI1638595T1 (sl) 2013-04-30
HRP20130242T1 (hr) 2013-04-30
DK1638595T3 (da) 2013-04-08
AU2004248931A1 (en) 2004-12-29
JP2009514777A (ja) 2009-04-09
US20070059252A1 (en) 2007-03-15
EP1638595A1 (en) 2006-03-29
NO330210B1 (no) 2011-03-07
AU2004248931B2 (en) 2009-07-16
PL1638595T3 (pl) 2013-06-28
US7740884B2 (en) 2010-06-22
PT1638595E (pt) 2013-04-26
IL172353A (en) 2013-04-30
ES2414705T3 (es) 2013-07-22
CA2526099C (en) 2013-02-05

Similar Documents

Publication Publication Date Title
NO20060241L (no) Frysetorket FSH/LH-formuleringer
HUP0400390A2 (hu) Tetrahidrokinolin-származékok és ezeket tartalmazó gyógyszerkészítmények
BRPI0312472B8 (pt) composição compreendendo dois complexos iscom diferentes
CY1119723T1 (el) Φαρμακοτεχνικες μορφες πεπτιδιου περιεχουσες προπυλενογλυκολη οι οποιες ειναι βελτιστες για παραγωγη και για χρηση σε συσκευες ενεσεων
AR043972A1 (es) Formulaciones farmaceuticas de fsh y lh
NO20070248L (no) Fremgangsmater for fremstilling av gonadotropinfrigjorende hormon reseptor antagonister
EP2279754A3 (en) Remodelling and glycoconjugation of human growth hormone (hGH)
NO20025777D0 (no) Brönnsement-blanding og additiv for slik blanding
HUP0402067A2 (hu) Oltóanyagok
SE0100568D0 (sv) Compounds
TWI263640B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CA2349142A1 (en) Compositions and methods for stimulating gastrointestinal motility
AU2002359727A8 (en) Fused cyclic modulators of nuclear hormone receptor function
WO2002085311A3 (en) Hcg formulation
HUP0402656A2 (hu) Sejtterápiás eljárás tumorok kezelésére
CO5300414A1 (es) Composiciones de vacunas con antigenos de streptococus de virus vsr y adyuvante estimulador de respuesta th1
NO20026167D0 (no) Kondenserte cykliske forbindelser som modulatorer av nukle¶r hormon reseptor funksjon
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
WO2003076600A3 (en) In vitro maturation of immature human oocytes
NO20005145D0 (no) FremgangsmÕte for behandling av fertilitetsproblemer
IT1261471B (it) Composizione farmaceutica per somministrazione rettale nel trattamentodi cefalea e relativo metodo di preparazione ed impiego.
ATE491464T1 (de) Lh zur verwendung der erhaltung einer oder mehreren schwangerschaften durch induktion der bildung des sekundären gelbkörpers.
MXPA04001976A (es) Hormona de crecimiento humano modificada.
UA91960C2 (ru) Жидкие фармацевтические композиции fsh и lh
TW200503750A (en) FSH and LH pharmaceutical formulations